The Anti-VEGF Market segment is typically analyzed across three main criteria: application, molecule type, and end-user. The application segment is dominated by ophthalmic indications, including wet AMD, DME, and RVO, which collectively account for the largest share of revenue due to the chronic nature of treatment. The oncology segment, encompassing applications in colorectal, lung, and ovarian cancers, represents a substantial, albeit smaller, segment. Segmentation by molecule type is crucial, dividing the market between monoclonal antibodies (like bevacizumab and ranibizumab) and fusion proteins (like aflibercept), each with distinct market shares and competitive dynamics.

End-user segmentation separates the market into hospitals, specialty clinics, and ambulatory surgical centers (ASCs). ASCs and specialty clinics are showing the fastest growth, as they are increasingly becoming the preferred setting for routine, high-volume intravitreal injections due to efficiency and lower overhead costs compared to large hospitals. Understanding these segments is vital for manufacturers to tailor their commercial strategies, whether they are targeting the high-volume hospital segment with oncology indications or the specialty ophthalmic clinics for chronic retinal disease management.